TheraVectys is an innovative immunotherapy company that aims to revolutionize global healthcare by developing effective treatments and preventive measures for cancers and major infectious diseases. As a spin-off from the prestigious Institut Pasteur, TheraVectys holds an exclusive global licensing agreement on Lentiviral Vectors for Vaccine Applications, which allows them to deliver groundbreaking medicines. Unlike traditional vaccines, TheraVectys' proprietary lentiviral vector immunotherapy stimulates the production of high-quality T cells and antibodies, resulting in robust and long-lasting protective or therapeutic immunity against diseases such as AIDS, malaria, and tuberculosis.

Their modified lentiviral vectors possess exceptional properties such as non-integrative viral DNA, advanced DNA flap technology for gene transfer, and targeted dendritic cell activation. Headquartered in Paris and the USA, TheraVectys collaborates closely with the Institut Pasteur, leveraging over 20 years of fundamental research and a vast intellectual property portfolio to develop a pipeline of vaccine candidates. Through strategic partnerships in research, production, clinical development, and commercialization, TheraVectys is poised to save millions of lives with their groundbreaking technology and solutions